Ludwig Enterprises Inc
ludwigent.comWhat Do They Do?
Develops mRNA-based screening tests for inflammation-related diseases, including cancer, for patients reached through healthcare providers and clinical laboratories.
10-K for FY2025, filed Mar 16, 2026Ludwig is an early-stage genomic technology company focused on developing screening tests for inflammation-related chronic diseases…View ↗
Our business model combines a business-to-business-to-consumer (B2B2C) strategy with partnerships through CLIA-certified laboratories. We…View ↗
Our initial product candidate is the Revealia™ Breast test, a non-invasive cheek swab assay designed to detect molecular signatures in mRNA…View ↗
Our business-to-business-to-consumer (B2B2C) strategy emphasizes institutional and clinically affiliated distribution through healthcare…View ↗
How Do They Make Money?
$217
-
10-K for FY2025, filed Mar 16, 2026
$217 ↗
Who Are Their Customers?
Healthcare providers and affiliated organizations, including hospitals, cancer centers and physician networks, are expected to connect patients with the test. Independent laboratories are also expected to provide it, while home kits are planned for patients.
10-K for FY2025, filed Mar 16, 2026Our business model combines a business-to-business-to-consumer (B2B2C) strategy with partnerships through CLIA-certified laboratories. We…View ↗
We intend the Revealia™ Breast test to serve as a screening tool that may indicate whether an individual should undergo further diagnostic…View ↗
Our business-to-business-to-consumer (B2B2C) strategy emphasizes institutional and clinically affiliated distribution through healthcare…View ↗
In this model, hospitals, cancer centers, physician networks, or other clinically affiliated partners introduce the test within established…View ↗
Do Revenues Turn Into Profits?
No. It lost $3M in FY2024.
10-K for FY2025, filed Mar 16, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 29, 2026
$218.8KView ↗
- ▲ Now profitable
- vs −$540.9K in Q1 FY2025
Who Do They Compete With?
Competes with 23andMe, Natera, Guardant Health, Exai Bio, Exact Sciences, GRAIL, Freenome Holdings, DELFI Diagnostics, and Avantect (ClearNote Health)
10-K for FY2025, filed Mar 16, 2026Many of these entities have significantly greater financial, technical, and commercial resources than we do, as well as established…View ↗
Loading...
